US EditionPublished • loading... • Updated
SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly
Summary by Benzinga
20 Articles
20 Articles
SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly
Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company ("Lilly"). The companies will collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio's proprietary tissue selective delivery te…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources20
Leaning Left2Leaning Right1Center6Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 22%
C 67%
11%
Factuality
To view factuality data please Upgrade to Premium
